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Abstract: Raltegravir is the first licensed compound in 2007 of the new integrase inhibitor 
drug class. At the dose of 400 mg twice daily, raltegravir showed a potent antiviral action in 
antiretroviral-naïve patients when associated with tenofovir and emtricitabine. Raltegravir was 
also found to be highly active in antiretroviral-experienced patients with virological failure and 
displaying multiresistant virus, as shown with the BENCHMRK and ANRS 139 TRIO trials. 
Finally, the use of raltegravir was assessed in the context of a switch strategy in antiretroviral-
experienced patients with virological success [human immunodeficiency virus type 1 (HIV-1) 
RNA below detection limit], highlighting the following mandatory criteria in this strategy: the 
nucleoside reverse transcriptase inhibitors associated with raltegravir have to be fully active. In the 
different studies, raltegravir had a favorable safety and tolerability profile. In the   clinical situation 
a switch in virologically suppressed patients receiving a protease inhibitor, an improvement of 
the lipid profile was observed. Overall, when analyzing the Phase II and III trials together, only 
a few patients on raltegravir discontinued for adverse events. The development of resistance to 
raltegravir mainly involved three resistance mutations in integrase gene: Q148H/K/R, N155H, 
and Y143C/H/R. In conclusion, raltegravir improved the clinical management of HIV-1 infection 
both in antiretroviral-naïve and in antiretroviral-experienced patients.
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Rationale for the development of new  
antiretroviral drugs in HIV infection management
Since 1996, highly active antiretroviral therapy is still the standard of care for patients 
infected with human immunodeficiency virus (HIV) and displaying advanced immuno-
deficiency.1 Combination regimens have resulted in improved survival and decreased 
morbidity for patients with a CD4 cell count below 350 cells/mm3.2 However, viral 
suppression cannot always be achieved or sustained with standard antiretroviral-based 
regimens because of the development of viral resistance, toxic effects of drugs, drug 
intolerance, or problems of adherence.3 The majority of HIV-infected patients in whom 
highly active antiretroviral therapy fails displayed plasma-resistant virus.4 When only 
two viral enzymes (ie, reverse transcriptase and protease) were targeted by antiretroviral 
drugs, cross-resistance rapidly limits therapeutic options. Thus, antiretroviral drugs 
directed at new HIV targets were urgently needed for patients exhibiting detectable 
viremia despite treatment.
In this context, HIV type 1 (HIV-1) integrase represented one of the possible new 
therapeutic target.5,6 Consequently, HIV-1 integrase inhibitors would be expected 
to retain activity against HIV-1 that is resistant to other classes of antiretroviral Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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drugs. In October 2007, raltegravir (MK-0518; Isentress, 
Merck, Whitehouse Station, NJ) was the first approved 
HIV-1 integrase inhibitor; it targets the strand transfer step 
of HIV-1 integration. It is currently approved by the US 
Food and Drug Administration in a large indication: “in 
combination with other antiretroviral agents for the treatment 
of HIV-1 infection in adult patients” without any specific 
criteria, both in antiretroviral-naïve and in antiretroviral-
experienced patients.
Twenty years after the discovery of the therapeutic   activity 
of zidovudine, the first antiretroviral drug used in the clinic, 
more than 25 antiretroviral drugs are now available, repre-
senting six different drug classes.
Overview of pharmacology and 
mechanism of action of raltegravir
Mechanism of action
The complete viral life cycle requires integration of HIV-1 
viral DNA into the host cell genome. It occurs in three steps 
(Figure 1).5,7,8 The double-stranded DNA copy generated by 
reverse transcription of the HIV-1 viral RNA genome is a part 
of the “preintegration complex”, containing both cellular and 
viral proteins, including integrase. In a first step, termed “3′ 
processing”, two nucleotides are removed from the 3′ ends 
of the viral DNA. In a second step, termed “strand transfer”, 
the proviral DNA is inserted into the host DNA and joined 
with it. Then, gaps in DNA are repaired by cellular enzymes 
by removing the two unpaired nucleotides at the 5′ end of 
the proviral DNA. The HIV integrase catalyses all steps 
of integration process except the last one, ie, DNA repair 
and ligation. A large series of selective inhibitors of strand 
transfer, β-diketo acid derivates, were tried to be developed 
as orally bioavailable agents.6,9–12 Mechanistic studies showed 
that L-731,988, a β-diketo acid derivate, recognizes and selec-
tively binds the integrase donor substrate complex exclusively 
in the context of catalytically active protein assembled on the 
viral DNA end. Thus, L-731,988 binds within the integrase-
active site and inhibits strand transfer by competing with the 
target DNA substrate.13
Chemical optimization of these compounds led to 
  naphthyridine derivatives and L-900612 or MK-0518 
(raltegravir) as a promising candidate compound. A recent 
study based on the diffracting crystals of the full-length 
integrase from the prototype foamy virus in complex with 
its cognate viral DNA enabled to determine more precisely 
the contacts between raltegravir and integrase structure.14 
The latter particularly included the metal cofactors of the 
active site, the bases of the invariant CA dinucleotide, and 
integrase residues 212, 214, and 215. Thus, the mechanism 
of action of the integrase strand-transfer inhibitors was more 
precisely described. Thus, the drug binding to integrase leads 
to the displacement of the reactive viral DNA end from the 
active site, disarming the viral nucleoprotein complex.14 This 
could explain why the integrase strand-transfer inhibitors 
preferentially interact with and inhibit the DNA-bound form 
of HIV-1 integrase.14
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Figure 1 Steps of viral integration. Copyright © 2002. Reproduced with permission from NCBI DNA Replication, Repair, and Recombination. In: “Basic Genetic Mechanisms”, 
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Figure 2 Change from baseline at day 10 in HIv-1 RNA log10 copies/mL (with 95% CI). error bars indicate 95% CI. Data for a total of 7 patients (from 4 of the 5 treatment 
groups) were not available on day 5. Copyright © 2007. Adapted with permission from Markowitz M, Nguyen BY, Gotuzzo e, et al. Rapid and durable antiretroviral effect of the 
HIv-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naïve patients with HIv-1 infection: results of a 48-week controlled study. J Acquir Immune Defic 
Syndr. 2007;46(2):125–133.
Raltegravir has potent in vitro activity against HIV-1, 
with a 95% inhibitory concentration (IC95; ±SD) in human 
T lymphoid cell cultures of 31 ± 20 nmol/L. It is active against 
a wide range of wild-type and drug-resistant HIV-1 isolates 
harboring resistance mutations in reverse transcriptase and 
protease coding regions, including both virus using CCR5 
coreceptor and CXCR4 coreceptor.9
The in vivo activity of raltegravir was first described in 
the Phase II protocol 004, in which increasing doses of 100, 
200, 400, and 600 mg of raltegravir administrated twice 
daily were compared with the placebo.15 Thirty-five subjects 
received a 10-day course of raltegravir monotherapy at the 
doses described earlier or placebo. After 10 days, the mean 
HIV-1 RNA decrease was 1.66–2.16 log10 copies/mL in 
raltegravir recipients as compared with 0.17 log10 copies/mL 
in placebo-treated patients. No significant difference in HIV-1 
RNA decrease was evidenced in the different   raltegravir 
arms (Figure 2).
Thus, in vitro and in vivo activities of raltegravir 
against HIV-1 were demonstrated. Furthermore, additive or 
synergistic activity was observed when cell culture samples, 
infected with HIV-1, were incubated with raltegravir and a 
panel of available nucleoside analog reverse transcriptase 
inhibitors (NRTI), nonnucleoside reverse transcriptase inhibi-
tors (NNRTI), and protease inhibitors (PI). Taken together, 
these findings argue for the use of raltegravir with other active 
antiretroviral drugs.
Pharmacology of raltegravir
Oral absorption of raltegravir is rapid with a median time 
to maximum concentration of 0.5–1.3 hours, and oral 
  bioavailability is approximately 30%.16 Plasma protein 
binding reaches 83%. There was a biphasic decrease in 
drug concentrations, with an initial-phase half-life of 
∼1 hour and a terminal-phase half-life of 7–12 hours 
(Merck). These characteristics were not affected by food Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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with moderate-to-high fat content. Raltegravir is mainly 
  metabolized by the glucuronidation enzyme UGT1A1, not 
by the CYP450 enzyme system. Thus, the potential for 
  drug–drug interactions is decreased and   administration 
of raltegravir may be of interest in combination with 
  anti  tuberculosis drugs or immunosuppressive agents, for 
example, with the exception of rifampicin. Thus, rifampicin 
is the inducer of UGT1A1, resulting in lower plasma ralte-
gravir concentrations and needing to double the raltegravir 
dose to 800 mg.17 Finally, excretion in feces and in urine 
accounts for most of the elimination.
Raltegravir is administered twice daily. No dose adjust-
ments are recommended for severe renal impairment or 
mild-to-moderate hepatic impairment. The independence of 
the compound from “boosting” of drug levels with ritonavir 
is an attractive feature for many patients suffering from 
ritonavir-associated side effects. Interestingly, atazanavir 
inhibits UGT1A1, thus atazanavir is a likely combination 
partner for raltegravir, and pharmacokinetic studies with 
atazanavir, with or without ritonavir, showed a 30%–70% 
increase in raltegravir area under the plasma concentration 
time curve (AUC).18 However, further studies are needed to 
assess the clinical relevance of this mechanism.
Efficacy studies
Raltegravir-containing regimens were demonstrated to have 
potent antiretroviral activity and to be well tolerated in 
HIV-1-infected individuals. Clinical trials were performed 
in different groups of HIV-1-infected patients, ie, treatment-
naïve patients and antiretroviral-experienced patients with 
virological failure and exhibiting multiresistant plasma 
virus. Finally, the use of raltegravir was also assessed in 
switch strategy in antiretroviral-experienced patients with 
virological success.
Treatment-naïve patients
Patients included in the 10-day course of raltegravir 
  monotherapy protocol (protocol 004) described earlier 
(n = 30) and 171 additional patients were randomized to 
receive either raltegravir (100, 200, 400, or 600 mg twice 
daily) or efavirenz in combination with tenofovir and 
  lamivudine for 48 weeks.15 At baseline, mean viral load 
was 4.7 and 4.8 log10 copies/mL and mean CD4 cell count 
was 280 and 305 cells/mm3 in the raltegravir and efavirenz 
arms, respectively. At week 24, the HIV-1 RNA level 
was ,50 copies/mL in 85%–98% of raltegravir recipients 
and in 92% of efavirenz recipients. The mean change in 
CD4 cell count ranged from 144 to 221 cells/mm3 across all 
raltegravir groups at week 48. After week 48, all patients 
in the   raltegravir arms were given 400 mg twice daily. The 
virological response was sustained up to 96 weeks.19
This latter study confirmed the efficacy of raltegravir at 
the dose of 400 mg twice daily in antiretroviral-naïve patients, 
allowing to initiate Phase III trials using raltegravir-based 
regimen in first-line.
The STARTMRK study was an international, double-
blind, Phase III randomized, noninferiority trial.20 The 
study compared the safety and efficacy of raltegravir vs 
efavirenz in combination with tenofovir and emtricitabine 
in treatment-naïve patients. Inclusion criteria are as follows: 
HIV-1 infected patients naïve of antiretroviral treatment with 
HIV-1 RNA . 5000 copies/mL. Most patients were at an 
advanced stage of disease. Thus, 267 (47%) patients had a 
CD4 cell count of #200 cells/mm3 at baseline, of whom 58 
(22%) had #50 cells/mm3. More than half [n = 297 (53%)] of 
participants had HIV-1 RNA level of .5 log10 copies/mL.
In the main analysis that recorded as failures all patients 
who did not complete the study, 86.1% (n = 241) of the 
raltegravir group achieved the primary endpoint of ,50 cop-
ies/mL at week 48, compared with 81.9% (n = 230) of the 
efavirenz group [difference 4.2%, 95% confidence interval 
(CI): −1.9 to 10.3], indicating that raltegravir was noninferior 
to efavirenz (P , 0.0001 for noninferiority). The mean 
change in CD4 cell count at week 48 was 189 cells/mm3. The 
noninferiority of the raltegravir arm was also demonstrated 
in patients exhibiting HIV-1 RNA . 5 log10 copies/mL. 
Interestingly, the time to achieve such viral suppression was 
shorter for patients on raltegravir than those on efavirenz 
(log-rank test P , 0.0001) (Figure 3); however, the clinical 
significance of a more rapid HIV-1 RNA decline has not yet 
been established but might be of interest to limit the selec-
tion of drug-resistant variants during the phase of viral load 
decay.21
The results of the STARTMRK study at week 96 have 
recently been published and showed that the non-inferiority 
of raltegravir relative to efavirenz was sustained (difference 
2%, 95% CI: −4 to 9).22 Thus, raltegravir combined with 
tenofovir and emtricitabine is a durably efficacious regimen 
for treatment-naïve patients.
The results of the STARTMRK study led to the approval 
of raltegravir in antiretroviral-naïve patients.
Treatment-experienced patients  
with virological failure
Protocol 005 was a multicenter, randomized,   double-blind,   
placebo-controlled dose-ranging trial in treatment-experienced Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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patients.23 Inclusion criteria were as follows: HIV-1 infected 
patients with HIV-1 RNA . 5000 copies/mL and 
CD4 , 50 cells/mm3, on stable antiretroviral therapy for 
more than 3 months and infected with HIV-1 with docu-
mented genotypic or phenotypic resistance to at least one 
NNRTI, one NRTI, and one PI. One hundred seventy-
eight patients were included in this protocol. Investigators 
selected an optimal background regimen (OBR) according 
to all resistance tests available   during therapeutic history. 
Randomization was performed in a 1:1:1:1 fashion to 
raltegravir doses of 200, 400, and 600 mg twice daily, or 
placebo, stratified by PI resistance at baseline and prior 
enfuvirtide use. Primary end-points were response and 
toxicity on week 24. Virological response was significantly 
better for all raltegravir arms as compared to placebo, with 
no significant difference between the raltegravir arms. This 
difference in favor of raltegravir was observed with any 
extent of resistance to the compounds of the background 
regimen, as assessed by genotypic or phenotypic sensitivity 
scores corresponding to the number of drugs received by the 
patient predicted to be active at baseline. Use of additional 
enfuvirtide was also associated with a better virological 
outcome. The mean change in CD4 cell count from base-
line to week 24 was 113 cells/mm3 (95% CI: 73–150), with 
raltegravir 400 mg vs 5 cells/mm3 in the placebo group. 
There was no obvious difference of toxicity profile for any 
raltegravir dose in comparison with placebo.
The results of the protocol 005 confirmed the   efficacy 
of raltegravir at the dose of 400 mg twice daily in 
  antiretroviral-experienced patients, allowing to initiate Phase 
III clinical trials using raltegravir as part of a salvage regi-
men in patients with prior virological failures and exhibiting 
multidrug resistant virus.
Clinical trials BENCHMRK-1 (performed in Europe, 
Asia, the Pacific, and Peru) and BENCHMRK-2 (performed 
in the United States) were two parallel, double-blind, placebo-
controlled studies.24–26 In both trials, an investigator-selected, 
resistance analysis-based OBR was combined with either 
raltegravir or placebo. Randomization was performed in a 
2:1 manner. Four hundred sixty-two patients displaying triple-
class resistant virus at baseline and exhibiting plasma HIV-1 
RNA levels above 1000 copies/mL were included. The pri-
mary end-point was viral suppression to HIV-1 RNA , 400 
copies/mL at week 16, with virus suppression to HIV-1 RNA 
, 50 copies/mL and change from baseline viral load and CD4 
cell count evaluated as secondary end-points. The raltegravir 
arms in both trials were superior over placebo with regard to 
all end-points. The difference was maintained irrespective of 
the extent of baseline resistance (as assessed by genotypic 
and phenotypic sensitivity scores), baseline HIV-1 RNA 
levels, and baseline CD4 cell count. A superior response of 
raltegravir was sustained until week 24 in a combined analysis 
of both trials and confirmed after 48 weeks of follow-up. The 
difference in favor of raltegravir persisted regardless of the 
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background regimen. The mean change in CD4 cell count 
between baseline and week 48 was 109 cells/mm3 (95% 
CI: 98–121) in the raltegravir recipients as compared with 
45 cells/mm3 in the placebo recipients. The response rate 
(HIV-1 RNA , 50 copies/mL) in the raltegravir group at 
week 48 was 89% in the subgroup of patients receiving ralte-
gravir in association with enfuvirtide and darunavir, when 
both drugs were used for the first time.24 This approaches 
response rates in previously untreated patients and therefore 
represents a marked improvement for clinical management 
of patients with resistant virus. Results from combined 
BENCHMRK-1 and BENCHMRK-2   studies after 96 weeks 
of follow-up have been recently published, confirming the 
long-term efficacy of this strategy.23 Thus, 57% and 61% 
of the patients in the raltegravir arm,   compared with 26% 
and 28% of the patients in the placebo group, sustained 
an HIV-1 RNA level , 50 copies/mL and ,400 copies/mL 
at week 96, respectively, (P , 0.001 for both comparisons), 
demonstrating a superior and durable   virological efficacy of 
the raltegravir-based regimen.
Another trial assessing raltegravir in HIV-experienced 
patients in virological failure was the Agence Nationale 
de Recherches sur le SIDA (ANRS) 139 TRIO trial.24 
The   objective of the ANRS 139 TRIO trial was to assess 
the virological efficacy and safety of an antiretroviral regi-
men containing raltegravir and two new drugs: the   second 
generation NNRTI etravirine and darunavir boosted with 
ritonavir in HIV-1-infected patients who experienced 
  virological failure of a combination antiretroviral therapy 
and   displaying plasma multidrug-resistant virus. Patients 
enrolled in this noncomparative, open multicenter trial 
were naïve to the three investigational drugs and had plasma 
HIV-1 RNA   levels .1000 copies/mL, a history of virologi-
cal failure while receiving NNRTI, baseline plasma virus 
exhibiting $3 major PI-resistance mutations and NRTI 
resistance-associated mutations, and $3 darunavir and 
NNRTI resistance-associated mutations. The primary end 
point was the proportion of patients with plasma HIV-1 RNA 
levels ,50 copies/mL at week 24. A total of 103 patients were 
included, and 87% of them received an OBR that included 
NRTI (86 patients) or enfuvirtide (12 patients). At week 24, 
90% of patients (95% CI: 85–96) had an HIV-1 RNA level of 
,50 copies/mL. At week 48, 86% (95% CI: 80–93) had an 
HIV-1 RNA level of ,50 copies/mL. The median CD4 cell 
count increase from baseline to week 48 was 108 cells/mm3 
[interquartile range (IQR): 58–169]. Thus, highly antiretrovi-
ral-experienced patients harboring multidrug-resistant virus 
and who have few remaining treatment options may benefit 
from an antiretroviral therapy regimen containing three new 
drugs, raltegravir, etravirine, and darunavir/ritonavir, and may 
achieve high levels of virological suppression comparable to 
that of treatment-naïve patients.
Switch to raltegravir in treatment-
experienced patients with virological 
success
The aim of these studies was to evaluate a switch from 
enfuvirtide (ANRS 138 EASIER trial) or a boosted PI as 
lopinavir (SWITCHMRK trial) to raltegravir in virologically 
suppressed patients.
The SWITCHMRK 1 and 2 studies were   identically desig 
ned, double-blind, randomized, Phase III,   active-  controlled, non-
inferiority clinical trials.25 Patients   virologically   suppressed, 
receiving a lopinavir-based regimen for at least 3 months 
were included from 81 centers in five continents. The aims 
of the study were to assess the relative effects of a switch 
from lopinavir to raltegravir vs continuation of lopinavir 
on different parameters: i) serum lipid concentrations, ii) 
viral suppression, and iii) adverse events. In the combined 
analysis, viral suppression to ,50 copies/mL was achieved 
by 293 (84.4%) patients in the raltegravir group compared 
with 319 (90.6%) patients in the lopinavir group at week 24, 
failing to establish non-inferiority of raltegravir to lopinavir. 
The studies were terminated at week 24 because of lower 
than expected virological efficacy in the raltegravir group 
compared with the lopinavir group. Overall, 49 patients 
met the protocol definition of confirmed virological failure, 
32 in the raltegravir arm and 17 in the lopinavir arm. It is 
important to note that 18 (56%) and 4 (23%) patients had a 
history of virological failure on previous regimens, with the 
selection of NRTI resistance mutations, in the raltegravir and 
lopinavir arms, respectively. These results can be explained 
by the heterogeneous population enrolled in the SWITCH-
MRK studies. Of note, the inclusion criteria did not take 
account of genotypic resistance test criteria, or analysis of 
the patients’ antiretroviral history, including the occurrence 
of prior virological failure. Thus, it was not possible to 
ensure that the antiretroviral drugs present in the OBR were 
fully active. This study emphasizes that raltegravir had to be 
associated with fully active antiretroviral drugs to exclude a 
functional monotherapy context, which will strongly favor 
the development of resistance.
The SPIRAL study is a multicenter, noninferiority study 
assessing the efficacy of a switch from ritonavir-boosted PI to 
raltegravir in selected patients.27 To be included, the patients 
had to i) receive a ritonavir-boosted PI added to at least two Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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antiretroviral drugs and ii) show plasma HIV-1 RNA below 
50 copies/mL for at least the previous 6 months. At week 48, 
124 raltegravir recipients (89.2%) and 116 ritonavir-boosted 
PI recipients (86.6%) were still on virological success (dif-
ference 1.8%, 95% CI: −5.2 to 10.6), reaching noninferior 
efficacy. The differences of efficacy results observed between 
the SWITCHMRK and SPIRAL switch studies strengthen 
the need to reliably select the eligible patients for such 
strategies.
The ANRS 138 EASIER trial is a prospective, random-
ized, open-label, noninferiority trial to compare the antiviral 
efficacy and safety of a switch to raltegravir with the efficacy 
and safety of continuing enfuvirtide.28,29 Inclusion criteria 
were as follows: HIV-1-infected patients with multidrug-
resistant virus and exhibiting plasma HIV-1 RNA levels 
of ,400 copies/mL for at least 3 months with an enfuvirtide-
based regimen. A total of 170 patients were randomized 1:1 to 
maintain enfuvirtide or to switch to raltegravir. The switch to 
raltegravir was noninferior to the maintenance of enfuvirtide, 
with only one patient experiencing virological failure in each 
arm, leading to a difference of 0.01% between   treatments 
(95% CI: −6.7–6.8). At week 24, 88% of patients in both arms 
had plasma HIV-1 RNA levels of ,50 copies/mL. Thus, a 
switch from enfuvirtide to raltegravir within a virologically 
suppressive regimen was successful in maintaining inhibition 
of plasma HIV-1 replication at least over 24 weeks. A long-
term follow up is needed to accurately confirm the sustained 
efficacy of this strategy.
HIv genetic diversity and antiretroviral 
activity of raltegravir
HIV is characterized by high level of genetic diversity, within 
HIV-1 and HIV type 2 (HIV-2). HIV-1 is subdivided into four 
groups: M (major), O (outlier), N (non-M/non-O), and P.
Despite 40% of heterogeneity between the HIV-1 and 
HIV-2 integrase genes, the in vitro phenotypic susceptibility 
of HIV-2 clinical isolates to raltegravir was found in similar 
range to that of HIV-1.30 In addition, previous studies reported 
a potent in vivo clinical and virological efficacy of raltegravir 
in HIV-2 infected patients.31,32
HIV-1 group O (HIV-O) is endemic in Western Central 
Africa, including Cameroon, where the prevalence of this 
group is estimated at about 1% of all HIV infections. HIV-O 
displays strong genetic divergence from HIV-1 group M 
and a high degree of intragroup diversity. A study assessing 
  integrase polymorphism of 117 HIV-O clinical samples 
suggests that HIV-O presents natural mutations associated 
with in vitro or in vivo resistance to integrase inhibitors in 
HIV-1 group M genetic context.33 However, preliminary data 
reported on in vivo virological response in a few   number 
of HIV-O-infected patients receiving raltegravir-based 
regimen.34,35
Safety and tolerability
Overall, tolerability of raltegravir in clinical trials was excel-
lent, and the toxicity profile of this drug is nonoverlapping 
with other agents, with no clear neuropsychiatric, gastroin-
testinal, or metabolic toxicity.
In the protocol 004, adverse events were infrequent, 
of mild to moderate intensity, with no obvious difference 
between the treatment arms.15,19
In the STARTMRK studies, significantly more patients 
on efavirenz than on raltegravir had clinical adverse events 
that were judged to be drug-related. Post-hoc analysis showed 
that 16% and 32% of patients on raltegravir and efavirenz, 
respectively, had drug-related clinical adverse events of 
moderate-to-severe intensity (P , 0.0001).20,22 Specific 
drug-related clinical adverse events of any severity occur-
ring in more than 10% of participants on either raltegravir or 
efavirenz were dizziness, headache, and abnormal dreams. 
Immune reconstitution syndrome was reported as an adverse 
event in 17 (6%) raltegravir recipients and 11 (4%) efavirenz 
recipients. Analysis at week 8 showed that at least one central 
nervous system (CNS)-related adverse event had occurred in 
10% of patients on raltegravir vs 18% of those on efavirenz 
(P = 0.0149). Serious adverse events occurred at a similar fre-
quency in both treatment groups. Fewer laboratory-associated 
adverse events were recorded in patients on raltegravir than 
on efavirenz, but the difference was not significant. At week 
48, the mean changes from baseline in total cholesterol, LDL-
cholesterol, HDL-cholesterol, and triglyceride concentrations 
were smaller for raltegravir than for efavirenz recipients and 
the change in the total cholesterol/HDL-cholesterol ratio 
between treatment groups was not significant. At week 96 of 
the STARTMRK studies, fewer drug-related clinical adverse 
events (47% vs 78%; P , 0.001) occurred in raltegravir than 
in efavirenz recipients. Both regimens had modest effects on 
serum lipids and glucose levels and on body fat composi-
tion. Consistent with the week 48 findings, mean changes 
from baseline in total cholesterol, LDL-cholesterol, HDL 
cholesterol, and triglyceride levels were smaller in raltegravir 
than in efavirenz recipients at week 96 (P , 0.001 for each 
comparison).22 Changes in fat content at each time point 
were comparable in both treatment groups. Relatively few 
patients who had not developed drug-related clinical adverse 
events after 48 weeks of the study later developed such side Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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effects. Serious adverse events and   discontinuations due to 
adverse events were comparably infrequent in both treat-
ment groups.
The protocol 005 and the BENCHMRK studies were 
not the most appropriate trials to assess the safety pro-
file of raltegravir because all participants included in 
these   studies previously received complex regimens and 
were highly pretreated.23–25 However, side effects and labo-
ratory  abnormalities were balanced between the groups in 
both   trials, with no significant difference between the study 
arms. Of note, no dose-related toxicities were reported in the 
Phase II protocol 005 dose-ranging trial.23 In the BENCH-
MRK studies, a disproportionate diagnosis of several cancers 
was observed in the raltegravir groups (1.3%) as compared 
with the placebo groups (0.3%) at the time of the 16-week 
analyses.24,25 Following these preliminary results, a global 
analysis including all Phase II and Phase III raltegravir 
  studies, as well as data from the expanded access program, 
was performed, showing an adjusted risk of malignancy per 
100 patient-years not significantly different (2.5% in the 
raltegravir group vs 1.9% in the group of control subjects; 
Merck).
The ANRS 139 TRIO trial was an open trial without 
  control arm, so it is difficult to identify which adverse 
events were related to the investigational drugs: raltegravir, 
etravirine, and darunavir boosted with ritonavir.36 In this 
study, grade 3 or 4 clinical adverse events were reported in 
15 patients (14.6%) and only one patient discontinued the 
regimen because of an adverse event. This combination was 
well tolerated, most drug-related adverse events proved to be 
mild or moderate in severity.
The SWITCHMRK studies, assessing the switch from 
lopinavir to raltegravir in virologically suppressed patients, 
are of interest because two of the three primary endpoints of 
the study carried out the safety profile: i) the mean percentage 
change in serum lipid concentrations from baseline to week 
12 and ii) the frequency of adverse events up to 24 weeks.30 
At week 12, percentage changes in lipid concentrations 
(total cholesterol, non-HDL cholesterol, and triglycerides) 
from baseline were significantly greater (P , 0.0001) in 
raltegravir recipients than in lopinavir recipients. In the 
combined analysis, the changes in lipid concentrations for 
the raltegravir group compared with the lopinavir group 
were −12.6% vs 1.0% for total cholesterol, −15.0% vs 2.6% 
for non-HDL cholesterol, and −42.2% vs 6.2% for triglycer-
ides. Changes in LDL cholesterol and HDL cholesterol were 
similar in the raltegravir and lopinavir groups. Clinical and 
laboratory adverse events occurred at similar frequencies in 
both treatment groups. There were no serious drug-related 
adverse events or deaths. Overall, virologically suppressed 
patients switching to raltegravir had significantly greater 
reductions in some lipid parameters such as total cholesterol 
and triglycerides. Similarly, the SPIRAL study demonstrated 
that switching to raltegravir was associated with significant 
decreases in plasma lipids (triglycerides, total, LDL, and 
HDL cholesterols; P , 0.0001 for each comparison) 
and total-to-HDL cholesterol ratio (P , 0.05) relative to 
  continuing ritonavir-boosted PI. In term of adverse events, 
their overall incidence was similar in the raltegravir group 
than in the PI group.
In the ANRS 138 EASIER trial, grade 3–4 adverse events 
and laboratory abnormalities were uncommon, not different 
between the treatment arms, and there was no difference in 
glucose levels between treatment arms.28
Thus, in the different studies, raltegravir had a favor-
able safety and tolerability profile compared with efavirenz 
in antiretroviral-naïve patients. In the clinical situation of 
a switch in virologically suppressed patients receiving a 
boosted PI-based regimen, an improvement of the lipid profile 
was observed. Overall, when analyzing the Phase II and III 
trials together, only a few patients on raltegravir discontinued 
the drug for adverse events.
HIV resistance to raltegravir
The development of resistance to raltegravir is associated 
with the selection of mutations in its viral target: integrase 
gene. Three major raltegravir resistance-associated mutations 
are characterized and frequently detected in vivo in case 
of virological failure on a raltegravir-containing regimen: 
Q148H/K/R, N155H, and Y143C/H.24,37 All these positions 
are located near the catalytic site of the enzyme. A recent 
crystal structure study enabled to describe the interactions 
between HIV-1 integrase residue Tyr 143 and the methyl-
oxadiazole group of raltegravir, which could explain the role 
of the Y143C/H/R mutations in the development of resistance 
to raltegravir.14 The presence of any of these key resistance 
mutations is sufficient to reach high level of   phenotypic 
resistance to raltegravir (at least fold change .15).38 
  Furthermore, in vitro selection experiments under drug pres-
sure showed the rapid appearance of virus with a high level 
of phenotypic resistance to raltegravir.39,40 Thus, raltegravir 
is considered as a molecule with a low genetic barrier to 
resistance. In most cases, the development of key raltegravir 
resistance-associated mutations is followed by the selection of 
secondary mutations specific to the resistance genetic path-
way. The secondary mutations G140A/S, E92Q, and T97A Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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are preferentially linked to the Q148, N155, and Y143 genetic 
pathways, respectively.40,41 Several studies reported that these 
primary resistance mutations Y143C/R, Q148H/K/R, and 
N155H represent mutually exclusive and nonoverlapping 
genotypic resistance pathways.41–43
In the BENCHMRK studies, a total of 105 of the 
462 patients receiving raltegravir (23%) had virological 
failure by week 48.24 Among these samples, integrase 
genotyping performed both at baseline and after virological 
failure showed that 68% had genotypic evidence of viral 
resistance to raltegravir. Virological failure was generally 
associated with mutations at one of the three residues: Y143, 
Q148, or N155, usually in combination with at least one 
other mutation.24
In the STARTMRK studies, in case of virological 
failure, genotypic resistance tests were performed only in 
samples with plasma HIV-1 RNA levels of .400 copies/mL. 
Among the eight eligible samples for this analysis in the 
raltegravir arm, four displayed resistant virus with key 
raltegravir resistance-  associated mutations at positions 143, 
148, and 155.20,22 Between weeks 48 and 96, 12 additional 
patients met the protocol definition of virological failure in 
the raltegravir group, and 4 had plasma HIV-1 RNA level 
of .400 copies/mL. None of the viruses from the four 
evaluable raltegravir recipients had detectable resistance to 
any of the drugs in their regimen.22 Of note, in both BENCH-
MRK and STARTMRK studies, integrase genotyping was 
  performed only in patients exhibiting HIV-1 RNA level .400 
  copies/mL for technical reasons; however, the selection of 
raltegravir resistance mutations has been previously described 
in the context of low-level viremia, between 100 and 400 
copies/mL.43–45
In the ANRS 139 TRIO trial, among the 103 patients 
included in the study, 14 had a virological failure, defined 
as a plasma HIV-1 RNA level .50 copies/mL at week 24 
or between week 24 and week 48 on two consecutive speci-
mens for those undetectable at week 24.36 HIV-1 RNA level 
at time of virological failure was low with a median of 90 
copies/mL. No raltegravir resistance-associated mutations 
were detected at time of virological failure either by bulk 
sequencing or by clonal analyses, performed in three 
subject, despite adequate plasma drug concentrations in 
almost all patients.46
In the ANRS 138 EASIER trial, no raltegravir resistance 
mutations was detected by direct sequencing in the only 
patient with virological failure according to the trial   criteria.28 
However, 39 (29%) of the patients in the   raltegravir arm 
of the EASIER study displayed at least one episode of 
low-level viremia on treatment and significant integrase 
resistance-associated mutations were detected in three 
subject (7.7%), including N155H in two subjects and P145S 
in one subject.45
In the SWITCHMRK studies, genotypic resistance 
  testing was done in 14 of 16 patients with confirmed viro-
logical failure and HIV-1 RNA . 400 copies/mL.30 Of the 
11 assessable patients who displayed a viral rebound on 
raltegravir-based therapy, virus with mutations known to 
confer raltegravir resistance was found in eight patients: 
N155H (n = 6); Q148H/K/R ± G140S (n = 2); Y143C (n = 1). 
In five of these eight patients, resistance mutations were 
also found in the reverse transcriptase. Of note, the studies 
were terminated at week 24 because of lower than expected 
virological   efficacy in the raltegravir group compared with 
the lopinavir group.30
Interestingly, in the drug class of integrase inhibitors, 
several studies reported on the replacement of one resistant 
pathway by another one in patients continuing on a failing 
raltegravir-containing regimen.41,42,47 Most of these shifts in 
raltegravir-resistance profiles were characterized by the loss 
of variants containing N155H and the emergence of vari-
ants containing Q148R/H or, in a few cases, Y143C/R.41,42,47 
Phenotypic studies assessing viral replicative capacity and 
phenotypic resistance levels of raltegravir-resistant viruses 
showed that among single mutants, the N155H had the 
highest selective-advantage profile.48 Among raltegravir-
resistant double mutants, the highest selective-advantage 
profile was seen with G140S + Q148H.48 This finding likely 
explains why N155H can be selected early in the course of 
raltegravir resistance evolution in vivo but is later replaced 
by genotypes of the Q148 pathway. The same mechanism 
was described for the Y143 resistance pathway. Indeed, 
the level of phenotypic resistance to raltegravir associated 
with N155H is always much lower than that associated with 
Q148 or Y143 mutation (.100 times higher).49 Moreover, 
the characterization of the phenotypic evolution showed that 
a switch from N155H to Y143C/R was linked to an increase 
in resistance to raltegravir.50 Taken together, these findings 
showed that these changes in phenotype may help to explain 
the shifts in integrase genotype under raltegravir treatment 
failure observed in different studies.41,42,47,49
Little is known about the role of integrase-mutated 
minority variants in the development of resistance to 
raltegravir. Previous studies assessed the presence of such 
quasispecies at the baseline of raltegravir-based regimen, 
using different sensitive techniques (ultra-deep sequencing, 
allele-specific PCR assay). Thus, integrase-mutated minority Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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variants were detected in some cases in minority proportions 
(,1%) at baseline; however, no impact of their presence on 
the virological outcome was evidenced.51–53
A question remains unclear; several studies actually 
described the absence of selection of raltegravir resistance-
associated mutations in patients exhibiting low-level viremia 
on raltegravir-based therapy.46,54,55 In all Phase II and Phase III 
clinical trials, only the current characterized raltegravir 
resistance-associated mutations are reported, but we can 
hypothesize that the presence of other determinants, either 
in the integrase region or located in other parts of the pol 
gene, could impact on resistance.
Conclusions, place of raltegravir  
in therapy
The international guidelines recommend the use of ralte-
gravir in different stages of HIV infection, corresponding 
to distinct profiles of clinical situations, as we described in 
this paragraph.
Guidelines from the European AIDS Clinical Society 
(EACS) include raltegravir (400 mg twice daily) as an 
alternative in the first-line regimen in antiretroviral-
naïve patients (http://www.europeanaidsclinicalsociety.
org/guidelinespdf). Regarding the use of raltegravir, the 
recently updated French 2010 recommendations (see 
http://www.sante-sports.gouv.fr/IMG/pdf/Prise_en_
charge_medicale_des_personnes_infectees_par_le_VIH.
pdf) were similar to the EACS ones. According to the 
recommendations of the Department of Health and Human 
Services, United States guidelines (see http://aidsinfo.
nih.gov/contentfiles/AdultandAdolescentGL.pdf), ralte-
gravir (400 mg twice daily) associated with tenofovir and 
emtricitabine is indicated as the preferred regimen for the 
first-line ART.
About the use of raltegravir in a switch strategy in patients 
virologically suppressed, the EACS switch strategy indicates 
that switching from a ritonavir-boosted protease   inhibitor to 
raltegravir in a antiretroviral-based regimen is only   possible 
if (1) there is no history of prior virological failure with 
plasma virus exhibiting NRTI resistance-associated muta-
tions and (2) NRTI backbone is fully active according to the 
different genotypic resistance tests available during the whole 
therapeutic history of the patient. A switch from enfuvirtide 
to raltegravir for simplification and adherence facilita-
tion can also be considered in patients with HIV-1 RNA 
, 50 copies/mL, following similar criteria to that described 
earlier for a ritonavir-boosted PI. Of note, the association 
of only one NRTI with raltegravir is not   recommended by 
the EACS.
In summary, raltegravir is a potent and well-tolerated 
antiretroviral drug, active in vivo against a large variety of 
HIV strains (HIV-1 group M non-B subtypes, HIV-1 group 
O, HIV-2) and with many possible clinical uses:
1.  in antiretroviral-naïve patients (associated with tenofovir 
and emtricitabine)
2.  in antiretroviral-experienced patients in virological 
  failure, associated with at least two fully active drugs
3.  in antiretroviral-experienced patients in virological 
  success (HIV-1 RNA , 50 copies/mL), associated with 
at least two fully active drugs and with no prior history 
of virological failure
In conclusion, the use of raltegravir had improved the 
clinical management of HIV-1 infection both in antiretroviral-
naïve and in antiretroviral-experienced patients. Ongoing 
clinical trials currently assess new therapeutic strategies such 
as antiretroviral bitherapy of raltegravir combined with a PI 
and a new therapeutic scheme with a daily-dosing strategy. 
Results from ongoing trials will also help to delineate the 
place of raltegravir in other clinical contexts, such as the 
particular case of post-exposure prophylaxis, the treatment of 
children or adolescents infected with HIV , pregnant women, 
and adults co-infected with HIV and tuberculosis.
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